Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UAE (United Arab Emirates) blood transfusion and screening procedures improve

This article was originally published in Clinica

Executive Summary

The UAE is to improve its blood transfusion services by extending the use of technology for removing leukocyte from blood by filtration. The ministry of health previously only allowed the process, known as leukodepletion, to be used in critical procedures such as dialysis and cases of patients with immune deficiencies. Dr Abdul Raheem Jaffar, under-secretary at the health ministry, told the Khaleej Times that the government's decision to extend leukodepletion, for which it spends Dh20 million ($5.4 million) a year was aimed at guaranteeing the safety of patients. He added that due to the strict criteria of donor selection, blood transfusion in the UAE was now 100% safe.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts